Dr. Cameron Brian Nabavi, MD

Dr. Nabavi practices at Eye Center of Columbus in Columbus, Ohio.

Dr. Nabavi's NPI, 1003093774, was assigned on January 24, 2008. Dr. Nabavi graduated from University of California, San Diego School of Medicine in 2006. Dr. Nabavi holds Ohio license 35.099896.

Dr. Nabavi's primary practice is Eye Center of Columbus, at 262 Neil Avenue, Suite 500, Columbus, OH 43215. The practice phone is (614) 827-6602.

Dr. Nabavi's primary practice is Eye Center of Columbus in Columbus, Ohio. Dr. Nabavi is also affiliated with OhioHealth Riverside Methodist Hospital. Dmand AI also links Dr. Nabavi to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nabavi practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Nabavi's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Nabavi is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Nabavi is licensed in Ohio.

CMS data shows 5,265 Medicare services from Dr. Nabavi across 19 procedure codes in 2024, for 629 Medicare patients. Medicare paid $248,469 for them.

CMS counts 629 Medicare patients who saw Dr. Nabavi in 2024. The largest group is 65 to 74, with 331 patients. 73% of them have high cholesterol, and 71% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.00, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Nabavi's median patient age at 70, with 62% women.

In 2024, Dr. Nabavi wrote 1,280 Medicare Part D claims for 653 patients. 68% of them were for generic drugs. CMS names the drug for 1,206 of them, across 10 drugs with 11 or more claims each, at $10,505 in total drug cost. In 2023, CMS named 1,071 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Nabavi for performance year 2024, reported as part of a group. Dr. Nabavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. Nabavi, more than 64% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Nabavi, published from 2011 to 2020. The most frequent topics are Dacryocystorhinostomy, Intubation and Postoperative Complications. Dr. Nabavi has published most often in Ophthalmic Plast Reconstr Surg. Dr. Nabavi's most frequent co-authors are Jeremiah P. Tao, MD, Kenneth Vern Cahill, MD and Craig N. Czyz, DO.

Dmand AI links Dr. Nabavi to 1 clinical trial. Conditions studied include Graves Ophthalmopathy and Exophthalmos.

CMS Open Payments shows 148 general payments to Dr. Nabavi from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Horizon Pharma plc paid the most, $658.

Dr. Nabavi graduated from University of California, San Diego School of Medicine in 2006.